JP2016520534A5 - - Google Patents

Download PDF

Info

Publication number
JP2016520534A5
JP2016520534A5 JP2016503642A JP2016503642A JP2016520534A5 JP 2016520534 A5 JP2016520534 A5 JP 2016520534A5 JP 2016503642 A JP2016503642 A JP 2016503642A JP 2016503642 A JP2016503642 A JP 2016503642A JP 2016520534 A5 JP2016520534 A5 JP 2016520534A5
Authority
JP
Japan
Prior art keywords
fusion protein
seq
sequence
nucleic acid
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016503642A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520534A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/055438 external-priority patent/WO2014147087A1/en
Publication of JP2016520534A publication Critical patent/JP2016520534A/ja
Publication of JP2016520534A5 publication Critical patent/JP2016520534A5/ja
Pending legal-status Critical Current

Links

JP2016503642A 2013-03-18 2014-03-18 インフルエンザ核タンパク質ワクチン Pending JP2016520534A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13305320.7 2013-03-18
EP13305320 2013-03-18
PCT/EP2014/055438 WO2014147087A1 (en) 2013-03-18 2014-03-18 Influenza nucleoprotein vaccines

Publications (2)

Publication Number Publication Date
JP2016520534A JP2016520534A (ja) 2016-07-14
JP2016520534A5 true JP2016520534A5 (enExample) 2017-04-13

Family

ID=48044708

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016503642A Pending JP2016520534A (ja) 2013-03-18 2014-03-18 インフルエンザ核タンパク質ワクチン

Country Status (11)

Country Link
US (2) US9243047B2 (enExample)
EP (1) EP2976357B1 (enExample)
JP (1) JP2016520534A (enExample)
KR (1) KR102379951B1 (enExample)
CN (2) CN105143251B (enExample)
AU (1) AU2014234363B2 (enExample)
BR (1) BR112015023738B8 (enExample)
CA (1) CA2901888C (enExample)
MX (1) MX363149B (enExample)
RU (1) RU2662667C2 (enExample)
WO (1) WO2014147087A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013357367B2 (en) * 2012-12-11 2019-10-24 Osivax Sas Modified coiled coil type proteins having improved properties
US20220184200A1 (en) * 2019-03-21 2022-06-16 Georgia State University Research Foundation, Inc. Virus-like particles and uses thereof
AU2022334800A1 (en) 2021-08-24 2024-02-15 Osivax Immunogenic compositions and their use
US20250121053A1 (en) 2021-12-22 2025-04-17 Osivax Vaccine compositions and their use
WO2023180394A1 (en) 2022-03-22 2023-09-28 Osivax Mrna vaccine compositions and their use
CN115779079A (zh) * 2022-10-01 2023-03-14 中国人民解放军军事科学院军事医学研究院 一种可增强与佐剂协同免疫效力的电荷调控型抗原蛋白
CN117659138B (zh) * 2023-12-25 2025-04-08 华中农业大学 一种流感病毒np蛋白突变体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108915A0 (en) * 1993-03-18 1994-06-24 Merck & Co Inc Polynucleotide vaccine against influenza virus
AU9222598A (en) * 1997-09-04 1999-03-22 Stanford University Reversible immobilization of arginine-tagged moieties on a silicate surface
AU2003263212A1 (en) * 2002-08-14 2004-03-03 Avidis Sa Heteropolymeric compound comprising a scaffold, an adjuvant and an antigen, and its use
CA2535517A1 (en) * 2003-08-12 2005-02-17 Avidis Sa Product comprising a c4bp core protein and a monomeric antigen, and its use
EP1795540A1 (en) * 2005-11-30 2007-06-13 Imaxio Multimeric complexes of antigens and an adjuvant
EP2060586A1 (en) * 2007-11-14 2009-05-20 PharmaSurgics in Sweden AB New synthetic arginine substituted peptides and their use
GB0918154D0 (en) * 2009-10-16 2009-12-02 Isis Innovation Mycobacterial vaccines
AU2013357367B2 (en) * 2012-12-11 2019-10-24 Osivax Sas Modified coiled coil type proteins having improved properties

Similar Documents

Publication Publication Date Title
JP2016520534A5 (enExample)
JP2016510983A5 (enExample)
EA201892250A1 (ru) Вакцина против rsv
JP2015525217A5 (enExample)
JP2016199557A5 (enExample)
JP2014507146A5 (enExample)
SA518390954B1 (ar) لقاحات علاجية لفيروس الورم الحليمي البشري 18
JP2013507907A5 (enExample)
BR112015001390A2 (pt) vacina de proteína de fusão multimérica e imunoterápicos
EA202090738A1 (ru) Способ безопасного индуцирования иммунитета против rsv
RU2015140603A (ru) Вакцины на основе нуклеопротеина вируса гриппа
JP2015212284A5 (enExample)
JP2015509707A5 (enExample)
BR112013032723A2 (pt) antígenos amplamente reativos computacionalmente otimizados para influenza h1n1
JP2016539946A5 (enExample)
MX340735B (es) Proteinas multimericas recombinantes de la influenza.
JP2015529678A5 (enExample)
JP2016509011A5 (enExample)
BR112014018884A2 (pt) antígenos amplamente reativos computacionalmente otimizados para viroses de influenza h3n2, h2n2, e b
JP2015524422A5 (enExample)
RU2014135053A (ru) Иммуногены для вакцинации против вич
EA201990718A1 (ru) Векторы аденовируса собачьих
JP2016504993A5 (enExample)
JP2015524403A5 (enExample)
AR128395A2 (es) Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9